CAL101

Name: CAL101
SKU: C0044
Availability: InStock

Product ID C0044

Cas No. 870281-82-6

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

CAL101 is an inhibitor of p110δ PI3K that is clinically used to treat leukemias such as mantle cell lymphoma and chronic lymphocytic leukemia (CLL). CAL101 exhibits anticancer chemotherapeutic and immunosuppressive activities. In mantle cell lymphoma cells, CAL101 induces G1 phase cell cycle arrest and apoptosis. In non-Hodgkin lymphoma and CLL cells, CAL101 inhibits downstream phosphorylation of Akt and induces apoptosis. Additionally, this compound inhibits cell chemotaxis, decreases chemokine production, inhibits migration, and prevents ERK- and Akt-dependent B-cell receptor signaling in CLL cells.

Product Info

Cas No.	870281-82-6
Purity	≥98%
Formula	C₂₂H₁₈FN₇O
Formula Wt.	415.42
IUPAC Name	5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
Synonym	Idelalisib, GS1101, CAL-101
Solubility	DMSO 83 mg/mL warmed (199.79 mM) Ethanol 23 mg/mL (55.36 mM) Water Insoluble
Appearance	White Crystal Powder

Shipping and Storage

Store Temp	4°C
Ship Temp	Ambient

Downloads

MSDS	C0044 MSDS PDF
Info Sheet	C0044 Info Sheet PDF
Brochures	PI3K-Akt-mTORC Pathway Booklet

References

Sanford DS, Wierda WG, Burger JA, et al. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk. 2015 Feb 19. [Epub ahead of print]. PMID: 25817936.

Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. PMID: 23676220.

Meadows SA, Vega F, Kashishian A, Johnson D, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012 Feb 23;119(8):1897-900. PMID: 22210877.

Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3603-12. PMID: 21803855.